Roquette Ventures Research
Investment Thesis
Roquette Ventures is the corporate venture capital arm of Roquette, the family-owned French group that makes plant-based ingredients, plant proteins and pharmaceutical excipients. Its own site describes it as a long-term strategic partner that invests in pharma and food and nutrition entrepreneurs, backing pioneering innovations that unlock the potential of nature. It says it helps the companies it backs accelerate their projects and grow by providing funding and support that draws on Roquette's know-how. The site says the unit was founded in 2010; a 2019 Roquette press release says 2015, and one directory says 2019, so the founding year is unclear.
The firm says it backs inspiring, passionate, forward-looking teams, projects that develop the best innovations for pharma and food and nutrition markets anywhere in the value chain, and innovative companies worldwide with growth potential.
Stated Focus Areas
The firm lists five main areas:
- Innovative solutions that disrupt traditional drug delivery.
- Plant-based ingredients with nutritional and functional benefits.
- High-performing plant-based specialties with sensory and technological advantages for cosmetics.
- Breakthrough technologies that improve manufacturing processes.
- New business models for bringing plant-based innovations to market.
The disclosed deals match this list: oral biologics delivery (Biograil), protein sweeteners (Magellan Life Sciences), plant-based whole-cut meat texturizing (Rival Foods), mycoprotein and fermentation proteins (The Protein Brewery, tozero), and human milk oligosaccharides for infant nutrition (Advanced Protein Technologies).
Stage Focus
Third-party profiles (DockWell) list pre-seed and seed through Series A/B and later. Disclosed deals are mostly seed and Series A, followed by participation in later rounds of existing portfolio companies such as Rival Foods (Series B) and Advanced Protein Technologies (follow-on). Roquette has also said it led the Magellan seed round.
Check Size
DockWell lists a typical investment of EUR 100K to EUR 1.5M. The firm does not publish check sizes, so confidence is low. The figures in the structured payload are stored as stated, without currency conversion.
Lead Tendency
Both. Roquette Ventures led the Magellan Life Sciences seed round and co-led the Rival Foods Series A with PeakBridge. It joined syndicates in Biograil (with Megatrend Invest, Verve, High-Tech Gruenderfonds, Sanner Ventures, Evonik Venture Capital and Eli Lilly), The Protein Brewery (led by Novo Holdings), and tozero (with Creadev, Clay Capital and IRD Invest).
Recent Activity
- November 2026: Biograil announced a EUR 20M round with Roquette Ventures in the investor group, following an 8.5M first close in July 2025.
- November 2024: participated in the tozero seed round.
- June 2025: supported the Rival Foods Series B alongside PeakBridge.
- April 2024: invested in Biograil.
- May 2023: sold Roquette Klotze / Algomed to NOAH Unternehmensgruppe.
Fund status is actively deploying, based on 2024 to 2026 deal flow. The unit invests from Roquette group balance-sheet capital, so there is no outside fund cycle and no published AUM.
Portfolio Highlights
The firm's website has no portfolio page. The companies below come from press releases and news coverage. Dealroom lists Accro, The Protein Brewery, Advanced Protein Technologies, Rival Foods and Magellan Life Sciences.
- Biograil (Denmark): BIONDD oral device that delivers biologics normally given by injection.
- Magellan Life Sciences (UK): Brazzein protein sweeteners.
- Rival Foods (Netherlands): shear-cell texturizing for plant-based whole cuts.
- The Protein Brewery (Netherlands): fermentation-derived mycoprotein (Fermotein).
- Advanced Protein Technologies (South Korea): human milk oligosaccharides.
- tozero (Germany): recycling technology.
- Accro: listed on Dealroom; no deal detail verified.
The one disclosed exit found is Roquette Klotze / Algomed, a Roquette unit sold to NOAH Unternehmensgruppe in 2023.
Team
- Edouard Nuttin: General Manager of Roquette Ventures in every press release found; Crunchbase calls him CEO. He is also Roquette's Group Head of Strategy and M&A and a board member of Roquette Ventures.
The firm's website names no other team members. The public contact is [email protected].
Decision Process
A corporate venture unit inside a family-owned industrial group. Decisions most likely sit with the General Manager and Roquette group management, and the investment thesis is tied to Roquette's own pharma and food and nutrition businesses. Warm intros are likely helpful, but the firm also invites direct contact by email.
Founder Preferences
Teams with strong technical differentiation that fit Roquette's markets. The firm offers strategic value beyond cash: excipient and plant-protein know-how, industrial scale-up and customer access. Founders should expect a strategic partner that may also want commercial agreements. Roquette has paired investments with commercial deals, for example with Advanced Protein Technologies in 2019.
Geographic Focus
Global, with the deals found concentrated in Europe (France, the Netherlands, Germany, Denmark, UK) plus South Korea. The firm says it invests in innovative companies around the world.
Gaps
No public portfolio page, no AUM, no published check size, and only one named team member. Founding year conflicts between sources (2010, 2015, 2019). Company domains were left null except Biograil.